Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714119 | 0.82 | S100A4 (0.47) | S100A4TRPV1KIF18AKMT2AMEN1 | |
| SCHEMBL30714322 | 0.82 | S100A4 (0.47) | S100A4TRPV1KIF18AKMT2AMEN1 | |
| SCHEMBL5305532 | 0.82 | S100A4 (0.47) | S100A4TRPV1KIF18AKMT2AMEN1 | |
| SCHEMBL5303668 | 0.82 | S100A4 (0.47) | S100A4TRPV1KIF18AKMT2AMEN1 | |
| SCHEMBL2646713 | 0.82 | VCAM1 (0.55) | S100A4TRPV1VCAM1POLB | |
| SCHEMBL1052777 | 0.80 | KIF18A (0.64) | KIF18AVCAM1MAPK1ALDH1A1POLB | |
| SCHEMBL30821752 | 0.80 | KIF18A (0.64) | KIF18AVCAM1MAPK1ALDH1A1POLB | |
| SCHEMBL17259 | 0.80 | ALDH1A1 (0.56) | S100A4KIF18AKMT2AMEN1MAPK1 | |
| SCHEMBL29430338 | 0.80 | ALDH1A1 (0.56) | S100A4KIF18AKMT2AMEN1MAPK1 | |
| SCHEMBL137704 | 0.79 | TSHR (0.58) | KIF18AKMT2AMEN1VCAM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106383-A1 | PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3512845-A1 | HEPATITIS B CORE PROTEIN MODULATORS | Assembly Biosciences, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| CN-109937201-A | HEPATITIS B CORE PROTEIN MODULATORS | 组装生物科学股份有限公司 | 2019-06-25 | — | — | CN | disclosed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053157-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2007039578-A1 | IMIDAZOLYL-SUBSTITUTED AZABENZOPHENONE COMPOUNDS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039581-A1 | IMIDAZOLYL-SUBSTITUTED DIAZABENZOPHENONE COMPOUNDS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-0384276-B1 | Water soluble azo compounds, method for their preparation and their use as dyestuffs | HOECHST AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0384276-A1 | Water soluble azo compounds, method for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | S100A4 1173/4885TRPV1 3650/4885KIF18A 3893/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | S100A4 1173/4885TRPV1 3650/4885KIF18A 3893/4885 |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | S100A4 4623/4885TRPV1 4822/4885KIF18A 3620/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | S100A4 1173/4885TRPV1 3650/4885KIF18A 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.